PEDIATRICS Vol. 77 No. 6 June 1986, pp. 932-933
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LEPOW, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEPOW, M. L.

Aplastic Anemia Following Chloramphenicol Therapy Still Happens!

MARTHA L. LEPOW MD1

1 Department of Pediatrics, The Albany Medical College of Union University, Albany, NY 12208

To the Editor.—

Chloramphenicol is still the drug of choice for treatment of ampicillin-resistant Haemophilus influenzae b meningitis, brain abscess,1 Rocky Mountain spotted fever in severely ill patients and young children, and typhoid fever. Intravenous oral and intraocular routes of administration have been widely used.

Smith and Webber2 have recently reviewed the pharmacology of chloramphenicol. Reversible erythroid suppression is dose related and more common in children. Genetic predisposition of the stem cell to inhibition of nucleic acid synthesis is thought to be the explanation for the "idiosyncratic" chloramphenicol-induced bone marrow aplasia, although Daum et al3 reported a probable dose-related case.